<DOC>
	<DOCNO>NCT01290133</DOCNO>
	<brief_summary>The purpose study describe safety tolerability pharmacokinetics single intravenous administration new , Sulfobutyl Ether-7-Beta-Cyclodextrin ( Captisolâ„¢ ) base , formulation Healthy Adult Subjects .</brief_summary>
	<brief_title>Single Dose Safety Study Compound Treat Post-Operative Nausea Vomiting ( PONV )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>1 . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . 2 . Male female 18 65 year age inclusive , time signing informed consent . 3 . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation HRT blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit completion followup assessment least 7 day study drug administration , whichever longer . 4 . Body weight great equal 50 kg BMI le equal 31 kg/m2 . 5 . Capable give write informed consent , include compliance requirement restriction list consent form . 6 . QTcB QTcF &lt; 450 msec ; QTcB QTcF &lt; 480 msec subject Bundle Branch Block . 7 . AST , ALT , alkaline phosphatase bilirubin great equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 1 . The subject positive prestudy drug screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . 2 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 3 . A positive test HIV antibody . 4 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 5 . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . 6 . Smoking regular use tobacco nicotinecontaining product within 2 week prior screen . 7 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 8 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 9 . History sensitivity heparin heparininduced thrombocytopenia ( clinic us heparin maintain intravenous cannula patency ) . 10 . Pregnant female determine positive serum urine hCG test screen prior dosing . 11 . Lactating female . 12 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 13 . Unwillingness inability follow procedure outline protocol . 14 . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . 15 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 16 . Exposure four new chemical entity within 12 month prior first dose day . 17 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>